PT - JOURNAL ARTICLE AU - Hongzhou Lu AU - Jingwen Ai AU - Yinzhong Shen AU - Yang Li AU - Tao Li AU - Xian Zhou AU - Haocheng Zhang AU - Qiran Zhang AU - Yun Ling AU - Sheng Wang AU - Hongping Qu AU - Yuan Gao AU - Yingchuan Li AU - Kanglong Yu AU - Duming Zhu AU - Hecheng Zhu AU - Rui Tian AU - Mei Zeng AU - Qiang Li AU - Yuanlin Song AU - Xiangyang Li AU - Jinfu Xu AU - Jie Xu AU - Enqiang Mao AU - Bijie Hu AU - Xin Li AU - Lei Zhu AU - Wenhong Zhang AU - on behalf of the Shanghai Clinical Treatment Expert Group for SARS-CoV-2 TI - A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention AID - 10.1101/2020.02.19.20025031 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.19.20025031 4099 - http://medrxiv.org/content/early/2020/02/23/2020.02.19.20025031.short 4100 - http://medrxiv.org/content/early/2020/02/23/2020.02.19.20025031.full AB - Objective To describe and evaluate the impact of diseases control and prevention on epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai.Design A retrospective descriptive studySetting ChinaParticipants Epidemiology information was collected from publicly accessible database. 265 patients admitted to Shanghai Public Health Center with confirmed COVID-19 were enrolled for clinical features analysis.Main outcome measure Prevention and control measures taken by Shanghai government, epidemiological, demographic, clinical, laboratory and radiology data were collected. Weibull distribution, Chi-square test, Fisher’s exact test, t test or Mann-Whitney U test were used in statistical analysis.Results COVID-19 transmission rate within Shanghai had reduced over 99% than previous speculated, and the exponential growth has been stopped so far. Epidemic was characterized by the first stage mainly composed of imported cases and the second stage where >50% of cases were local. The incubation period was 6.4 (95% CI 5.3 to 7.6) days and the mean onset-admission interval was 5.5 days (95% CI, 5.1 to 5.9). Median time for COVID-19 progressed to severe diseases were 8.5 days (IQR: 4.8-11.0 days). By February 11th, proportion of patients being mild, moderate, severe and critically ill were 1.9%(5/265), 89.8%(238/265), 3.8%(10/265), 4.5%(12/265), respectively; 47 people in our cohort were discharged, and 1 patient died.Conclusion Strict controlling of the transmission rate at the early stage of an epidemic in metropolis can quickly prohibit the spread of the diseases. Controlling local clusters is the key to prevent outbreaks from imported cases. Most COVID-19 severe cases progressed within 14 days of disease onset. Multiple systemic laboratory abnormalities had been observed before significant respiratory dysfunction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not fundedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available in the manuscript